{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ocrelizumab&page=2", "query": { "intervention": "Ocrelizumab", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ocrelizumab&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T17:56:46.218Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06677710", "title": "IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Sclerosis", "Primary Progressive Multiple Sclerosis (PPMS)", "Secondary Progressive Multiple Sclerosis (SPMS)", "Non-Active Secondary Progressive Multiple Sclerosis", "Non-Active SPMS", "Autoimmune Diseases of the Nervous System", "Nervous System Diseases", "Autoimmune Diseases", "Demyelinating Diseases", "Immune System Diseases", "Demyelinating Autoimmune Diseases, Central Nervous System (CNS)" ], "interventions": [ { "name": "IDP-023", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indapta Therapeutics, INC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 34, "start_date": "2026-06-30", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 5, "location_summary": "Stanford, California • Aurora, Colorado • Orlando, Florida + 2 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06677710" }, { "nct_id": "NCT03500328", "title": "Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq", "type": "OTHER" }, { "name": "Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 900, "start_date": "2018-05-02", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 47, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03500328" }, { "nct_id": "NCT06846281", "title": "Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Remibrutinib oral treatment", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "40 Years to 70 Years" }, "enrollment_count": 400, "start_date": "2025-06-23", "completion_date": "2031-06-25", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 44, "location_summary": "Scottsdale, Arizona • Irvine, California • Washington D.C., District of Columbia + 39 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06846281" }, { "nct_id": "NCT05232825", "title": "A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis", "Primary Progressive Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab IV", "type": "DRUG" }, { "name": "Ocrelizumab SC", "type": "DRUG" }, { "name": "Methylprednisolone IV", "type": "DRUG" }, { "name": "Diphenhydramine IV", "type": "DRUG" }, { "name": "Dexamethasone given orally", "type": "DRUG" }, { "name": "Desloratadine given orally", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 236, "start_date": "2022-05-03", "completion_date": "2025-06-06", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 7, "location_summary": "Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more", "locations": [ { "city": "Maitland", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Owosso", "state": "Michigan" }, { "city": "Dayton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05232825" }, { "nct_id": "NCT05123703", "title": "A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Ocrelizumab Placebo", "type": "OTHER" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Fingolimod Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "10 Years to 17 Years" }, "enrollment_count": 188, "start_date": "2022-05-19", "completion_date": "2029-09-17", "has_results": true, "last_update_posted_date": "2026-07-15", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 10, "location_summary": "La Jolla, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05123703" }, { "nct_id": "NCT04837651", "title": "Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis", "Demyelinating Autoimmune Diseases, CNS", "Autoimmune Diseases of the Nervous System", "Nervous System Diseases", "Demyelinating Diseases", "Autoimmune Diseases", "Immune System Diseases", "Pathologic Processes" ], "interventions": [ { "name": "Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test", "type": "DEVICE" }, { "name": "T-Detect COVID T-cell blood test", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Dragonfly Research, LLC", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 48, "start_date": "2021-03-02", "completion_date": "2021-07-01", "has_results": false, "last_update_posted_date": "2021-08-02", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 1, "location_summary": "Wellesley, Massachusetts", "locations": [ { "city": "Wellesley", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04837651" }, { "nct_id": "NCT02807285", "title": "Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Ocrelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2017-09-07", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 56, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Carmichael, California + 52 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Carmichael", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02807285" }, { "nct_id": "NCT00476996", "title": "A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Leflunomide", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 836, "start_date": "2007-05-15", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2019-08-12", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 144, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476996" }, { "nct_id": "NCT04796584", "title": "Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2022-07-11", "completion_date": "2022-10-25", "has_results": false, "last_update_posted_date": "2023-04-03", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04796584" }, { "nct_id": "NCT01412333", "title": "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Multiple Sclerosis" ], "interventions": [ { "name": "Interferon beta-1a", "type": "DRUG" }, { "name": "Ocrelizumab-matching placebo", "type": "DRUG" }, { "name": "Ocrelizumab", "type": "DRUG" }, { "name": "Interferon beta-1a-matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 835, "start_date": "2011-09-20", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2024-03-08", "last_synced_at": "2026-09-27T17:56:46.218Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 43 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01412333" } ] }